UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-38810

 

 

STEALTH BIOTHERAPEUTICS CORP

(Exact name of registrant as specified in its charter)

 

 

Stealth BioTherapeutics Corp

c/o Intertrust Corporate Services (Cayman) Limited

One Nexus Way, Camana Bay

Grand Cayman

KY1-9005 Cayman Islands

Telephone: (617) 600-6888

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Ordinary Shares, par value US$0.0003 per share

American Depositary Shares, each representing 12 ordinary shares

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: five

 

 

 


Pursuant to the requirements of the Securities Exchange Act of 1934, Stealth BioTherapeutics Corp has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    Stealth BioTherapeutics Corp
Date: November 28, 2022    
    By:  

/s/ Irene P. McCarthy

    Name:   Irene P. McCarthy
    Title:   Chief Executive Officer